PMID- 34282851
OWN - NLM
STAT- MEDLINE
DCOM- 20211027
LR  - 20211027
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 87
IP  - 10
DP  - 2021 Oct
TI  - Adverse events of recreational cannabis use reported to the French 
      addictovigilance network (2012-2017).
PG  - 3925-3937
LID - 10.1111/bcp.14812 [doi]
AB  - AIMS: To describe the adverse events (AEs) of recreational cannabis use in France 
      between 2012 and 2017. METHODS: AEs related to recreational cannabis use, alone 
      or in combination with alcohol and/or tobacco reported to the French 
      Addictovigilance Network were analysed (excluding cannabidiol and synthetic 
      cannabinoids). RESULTS: Reporting of AEs tripled between 2012 (n = 179, 6.3%, 95% 
      confidence interval [CI] = 5.4-7.2) and 2017 (n = 562, 10.1%, 95% CI = 9.3-10.9), 
      reaching 2217 cases. They concerned mainly men (76.4%) and users aged between 18 
      and 34 years (18-25: 30.9%; 26-34: 26.3%, range: 12-84 years). Cannabis was 
      mainly inhaled (71.6%) and exposure was most often chronic (64.2%). Many types of 
      AEs were reported: psychiatric (51.2%), neurological (15.6%), cardiac (7.8%) and 
      gastrointestinal (7.7%), including unexpected AEs (n = 34, 1.1%). The most common 
      effect was dependence, ranging from 10.1% (95% CI = 7.9-12.3) to 20.3% (95% 
      CI = 17.3-23.2) over the study period. Cannabinoid hyperemesis syndrome (n = 87, 
      2.8%) emerged from 2015. Deaths accounted for 0.2% of all AEs (4 men and 3 women 
      aged on average 35 years). A chronic pattern of cannabis use was reported in 4 of 
      them (intracranial hypertension in the context of lung cancer, suicide, cerebral 
      haematoma, neonatal death with concomitant chronic alcohol use), while in the 
      other cases the toxicological analysis identified cannabis use (ruptured aneurysm 
      and unknown aetiology). CONCLUSION: This study showed a multitude of AEs related 
      to recreational cannabis use, including unexpected AEs and deaths. It highlights 
      the problem of dependence and the emergence of cannabinoid hyperemesis syndrome.
CI  - (c) 2021 British Pharmacological Society.
FAU - Bouquet, Emilie
AU  - Bouquet E
AUID- ORCID: 0000-0002-2334-1022
AD  - Addictovigilance Center, Department of Clinical Pharmacology, Poitiers University 
      Hospital, France.
FAU - Pain, Stephanie
AU  - Pain S
AD  - Addictovigilance Center, Department of Clinical Pharmacology, Poitiers University 
      Hospital, France.
AD  - INSERM U-1084, Experimental and Clinical Neurosciences Laboratory, University of 
      Poitiers, Poitiers, France.
FAU - Eiden, Celine
AU  - Eiden C
AD  - Addictovigilance Center, Montpellier University Hospital, France.
FAU - Jouanjus, Emilie
AU  - Jouanjus E
AUID- ORCID: 0000-0002-3510-2475
AD  - Addictovigilance Center, Toulouse University Hospital, France.
FAU - Richard, Nathalie
AU  - Richard N
AD  - French National Agency for Medicines and Health Products Safety (ANSM), 
      Saint-Denis, France.
FAU - Fauconneau, Bernard
AU  - Fauconneau B
AD  - Addictovigilance Center, Department of Clinical Pharmacology, Poitiers University 
      Hospital, France.
FAU - Perault-Pochat, Marie-Christine
AU  - Perault-Pochat MC
AD  - Addictovigilance Center, Department of Clinical Pharmacology, Poitiers University 
      Hospital, France.
AD  - INSERM U-1084, Experimental and Clinical Neurosciences Laboratory, University of 
      Poitiers, Poitiers, France.
CN  - French Addictovigilance Network
LA  - eng
PT  - Journal Article
DEP - 20210419
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Cannabinoids)
RN  - 0 (Hallucinogens)
RN  - 19GBJ60SN5 (Cannabidiol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Cannabidiol
MH  - *Cannabinoids
MH  - *Cannabis
MH  - Child
MH  - *Hallucinogens
MH  - Humans
MH  - Infant, Newborn
MH  - Middle Aged
MH  - Vomiting
MH  - Young Adult
OTO - NOTNLM
OT  - addiction
OT  - addictovigilance
OT  - adverse events
OT  - deaths
OT  - hyperemesis syndrome
OT  - recreational cannabis
FIR - Batisse, Anne
IR  - Batisse A
FIR - Carton, Louise
IR  - Carton L
FIR - Chevalier, Cecile
IR  - Chevalier C
FIR - Daveluy, Amelie
IR  - Daveluy A
FIR - Fournier-Choma, Christine
IR  - Fournier-Choma C
FIR - Guerlais, Marylene
IR  - Guerlais M
FIR - Le Boisselier, Reynald
IR  - Le Boisselier R
FIR - Pochard, Liselotte
IR  - Pochard L
FIR - Revol, Bruno
IR  - Revol B
FIR - Tournebize, Juliana
IR  - Tournebize J
EDAT- 2021/07/21 06:00
MHDA- 2021/10/28 06:00
CRDT- 2021/07/20 08:43
PHST- 2021/02/23 00:00 [revised]
PHST- 2020/09/10 00:00 [received]
PHST- 2021/02/25 00:00 [accepted]
PHST- 2021/07/21 06:00 [pubmed]
PHST- 2021/10/28 06:00 [medline]
PHST- 2021/07/20 08:43 [entrez]
AID - 10.1111/bcp.14812 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2021 Oct;87(10):3925-3937. doi: 10.1111/bcp.14812. Epub 2021 
      Apr 19.